Alzamend Neuro: Ascendiant Capital lowers PT to $45, maintains Buy rating.

Thursday, Aug 21, 2025 6:01 am ET1min read

Alzamend Neuro: Ascendiant Capital lowers PT to $45, maintains Buy rating.

Alzamend Neuro: Ascendiant Capital lowers PT to $45, maintains Buy rating.

Comments



Add a public comment...
No comments

No comments yet